

SACCO
system



**Active Ingredients
and Services**

Resources

6,500+

Cell bank
proprietary
strains

45+

Probiotic species
manufactured

40,000L

Total fermentation
capacity

4

Pilot plants
up to 200L

90+

Years of probiotic
manufacturing

50+


University
Partnerships

110

Export
Countries

8

Production
Plants



Active**Ingredients**

Culture**Science**

Our CultureScience portfolio presents a selection of clinically studied strains, strategically formulated to address various essential health concerns across different life stages. Available as individual strains or pre-formulated blends, each product has undergone thorough evaluation in gold-standard human clinical trials, confirming its proven health benefits.

We adhere to the highest quality standards in the manufacturing of CultureScience strains, ensuring their sustained activity and viability throughout the entire shelf life of your finished product. Our commitment to quality reflects our dedication to providing reliable and effective solutions for the well-being of end-users.



Culture**Select**

Our CultureSelect portfolio offers a large selection of well-characterized strains with proven safety and which are produced under the highest quality standards to support your needs. CultureSelect strains provide a flexible solution to help you create unique formulations, with every product available as a single strain ingredient or a customized blend.



Gastrointestinal (GI) Health

Irritable Bowel Syndrome (IBS)	<i>B. coagulans</i> SNZ 1969™	Reduces the severity of IBS symptoms in over 90% of IBS-C and IBS-D patients after treatment of a minimum 30 days as well as improving their quality of life.	1 Bn CFU/day
Microbiota Balance	SYNBIO® <i>L. rhamnosus</i> IMC 501® <i>L. paracasei</i> IMC 502®	Successfully colonizes the gut, competing with and reducing harmful bacteria as well as enhancing bowel habits and well-being.	1 Bn CFU/day
Bloating, Gas, Heartburn	<i>B. coagulans</i> SNZ 1969™	Improves gut motility and constipation in healthy adults with abitudinal low intake of fruit and vegetables as well as relief from gas, heartburn and bloating.	15 Mn to 2 Bn CFU/day
Diarrhoea	<i>L. rhamnosus</i> CRL 1505®	Significantly decreases the impact of intestinal infections by reducing acute diarrhoea and the use of antibiotics in children.	100 Mn CFU/day
	<i>B. coagulans</i> SNZ 1969™	Improved watery stools in neonatal infants within 1 to 2 days and improved gastroenteritis in children up to 3 years of age within 3 days.	15 Mn to 2 Bn CFU/day
<i>Helicobacter pylori</i> infection	<i>L. fermentum</i> UCO-979C	Reduces pathogenic colonization in the gut, preventing infection and stimulating the immune system.	0,3 Bn CFU/day

Children and Infant Health

Respiratory and Diarrhoea	<i>L. rhamnosus</i> CRL 1505®	Significantly reduces upper respiratory tract infections, pharyngitis, tonsillitis, acute diarrhoea and the use of antibiotics.	0,1 Bn CFU/day
Infant Colic	<i>L. reuteri</i> LR 92	Maternal prenatal supplementation during the last 4 weeks of pregnancy reduces the incidence and severity of infantile colic in newborn babies.	0,1 Bn CFU/day
Otitis Media	<i>L. rhamnosus</i> LB21	Otitis media is the most common childhood infection. LB21 reduce incidence of this ear infection in children	1,5 Bn CFU/day

Women's Intimate Health

Vaginal Health	ProBioEtna CA15®	Restores a healthy vaginal microbiota after 10 days of treatment, reducing Vulvovaginal Candidiasis (VVC) and Bacterial Vaginosis (BV). Also helps to balance the vaginal microbiota.	10 Bn CFU/day
	SYNBIO® <i>L. rhamnosus</i> IMC 501® <i>L. paracasei</i> IMC 502®	Improves symptoms associated with bacterial vaginosis (BV) while decreasing the chances of recurrence by restoring vaginal microbiota balance. Also supports the gut microbiome and improves constipation, bloating and abdominal pain.	5 Bn CFU/day
	<i>L. plantarum</i> LB931™	A vaginally isolated <i>L. plantarum</i> with a human clinical study in vaginal health via topical application. This strain lowered mean vaginal pH, and inhibited group B streptococci. Also shows in-vitro reduction of Candida Albicans and inhibition of <i>E. coli</i> .	500 Mn CFU/day
	<i>B. coagulans</i> SNZ 1969™	Treatment in both oral and topical dose forms, this strain can reduce recurrent Bacterial Vaginosis (BV) and is effective against non-specific vaginitis.	150 Mn CFU/day

Immune Health

Upper Respiratory Tract	<i>L. rhamnosus</i> CRL 1505®	Decreases the severity of upper respiratory tract infection symptoms as well as decreasing the overall duration of the infection in children.	100 Mn CFU/day
	SYNBIO® <i>L. rhamnosus</i> IMC 501® <i>L. paracasei</i> IMC 502®	Decreases severity of symptoms of Upper Respiratory Tract infections.	1 Bn CFU/day

Allergy

Dust-Mites	SYNBIO® <i>L. rhamnosus</i> IMC 501® <i>L. paracasei</i> IMC 502®	Significantly reduces allergy sensitization to house dust mites.	15 Bn CFU/day
------------	---	--	---------------

Metabolic Health

Weight Management	<i>L. plantarum</i> IMC 510®	Supplementation for 12 weeks results in decreased body weight, waist circumference and BMI, which is maintained for 30 days after supplementation ceases .	15 Bn CFU/day
-------------------	------------------------------	--	---------------

Gut Brain Axis

Stress/Anxiety	<i>L. plantarum</i> P8	Supports a reduction in stress and anxiety, and improvements in memory and cognitive functions.	20 Bn CFU/day
----------------	------------------------	---	---------------

Oral Health

Dental Caries (Tooth Cavities)	<i>L. rhamnosus</i> SP 1	Regular intake reduces the occurrence of dental caries.	1.5 Bn CFU/day
	<i>L. rhamnosus</i> LB21	Reduces caries development and the number of days with antibiotic treatment by 60% in preschool children.	2 Bn CFU/day
	<i>B. coagulans</i> SNZ 1969™	Significant reduction of the cariogenic microorganism <i>Streptococcus mutans</i> in children.	150 Mn CFU/day
Aphthous Ulceration	<i>B. coagulans</i> SNZ 1969™	Significantly reduces the incidence of recurrent aphthous (mouth) ulcers.	150 Mn CFU/day

Skin Health

Acne	<i>L. rhamnosus</i> SP 1	Improves the appearance of acne and lessens the inflammatory processes related to acne formation by modulating genes involved in insulin signaling.	3 Bn CFU/day
Microbiota Balance	<i>L. rhamnosus</i> LB21	Significantly reduces the need to use corticosteroids in children.	100 Bn CFU/day
	<i>L. rhamnosus</i> LB21 + <i>L. rhamnosus</i> SP 1	Topical application decreases severity of visual signs and decreases intensity of itching on people with atopic dermatitis.	1 Bn CFU/day

Healthy Aging

Inflammaging and Sarcopenia	SYNBIO® <i>L. rhamnosus</i> IMC 501® <i>L. paracasei</i> IMC 502®	Supports healthy ageing by reducing chronic low-grade inflammation associated with age-related pathologies. May also reduce the risk of sarcopenia.	5 Bn CFU/day
--------------------------------	---	---	-----------------

Sport

Performance Improvement	SYNBIO® <i>L. rhamnosus</i> IMC 501® <i>L. paracasei</i> IMC 502®	Improves the body's recovery processes and fatigue after training by lowering exercise-induced oxidative stress. In addition, SYNBIO® improves gastrointestinal functions and reduces susceptibility to illness.	1 Bn CFU/day
----------------------------	---	--	-----------------

Postbiotics

Respiratory health	<i>L. rhamnosus</i> CRL 1505® HI	Thanks to the maintenance of higher levels of circulating dendritic cells involved in the anti-viral responses, it shows a beneficial role in promoting immune defense, with a reduction of symptomatic day of physical conditions.	1 Bn Cells/ day
-----------------------	----------------------------------	---	-----------------------

Probiotics

Species	Strain name	Minimum concentration (Billion CFU/g)*
<i>Bifidobacterium adolescentis</i>	SP 77	50
<i>Bifidobacterium animalis</i> subsp. <i>lactis</i>	Bi1	300
<i>Bifidobacterium animalis</i> subsp. <i>lactis</i>	BLC1	500
<i>Bifidobacterium bifidum</i>	SP 9	200
<i>Bifidobacterium breve</i>	Bbr8	300
<i>Bifidobacterium breve</i>	BL10	200
<i>Bifidobacterium infantis</i>	SP 37	300
<i>Bifidobacterium longum</i>	SP 54	100
<i>Lactobacillus acidophilus</i>	LA3	200
<i>Lactobacillus acidophilus</i>	LA1	200
<i>Lactobacillus brevis</i>	SP 48	200
<i>Lactobacillus bulgaricus</i>	LB2	50
<i>Lactobacillus casei</i>	BGP93	300
<i>Lactobacillus crispatus</i>	SP 28	50
<i>Lactobacillus crispatus</i>	SP 60	50
<i>Lactobacillus fermentum</i>	CS57	100
<i>Lactobacillus fermentum</i>	LF2	100
<i>Lactobacillus gasseri</i>	SP 33	200
<i>Lactobacillus gasseri</i>	SP 56	50
<i>Lactobacillus helveticus</i>	SP 27	100
<i>Lactobacillus lactis</i>	LL 82	100
<i>Lactobacillus paracasei</i>	101/37	200
<i>Lactobacillus paracasei</i>	BGP 2	400
<i>Lactobacillus plantarum</i>	14D	500
<i>Lactobacillus plantarum</i>	LB931	200
<i>Lactobacillus plantarum</i>	BG 112	400
<i>Lactobacillus rhamnous</i>	GG	350
<i>Lactobacillus salivarius</i>	SP 2	100
<i>Lactococcus lactis</i>	SP 38	300
<i>Streptococcus thermophilus</i>	Z57	200
<i>Streptococcus thermophilus</i>	SP 4	400

*1 Billion = 10⁹ CFU

Postbiotics

Species	Strain name	Minimum concentration (Billion Cells/g)*
<i>Bifidobacterium animalis subs. lactis</i>	BLC1 HI	600
<i>Bifidobacterium longum subs. infantis</i>	SP 37 HI	100
<i>Lactobacillus acidophilus</i>	LA1 HI	100
<i>Lactobacillus acidophilus</i>	LA 3 HI	150
<i>Lactobacillus casei</i>	BGP93 HI	150
<i>Lactobacillus paracasei</i>	101/37 HI	150
<i>Lactobacillus paracasei</i>	D3-5	150
<i>Lactobacillus plantarum</i>	14D HI	150
<i>Lactobacillus reuteri</i>	LR 92 HI	130
<i>Lactobacillus rhamnosus</i>	SP 1 HI	100
		*1 Billion = 10 ⁹ Cells



Each of the names of the products, ideas, brands, trademarks and logos mentioned in this document, however presented (i.e. displaying the ® or TM symbol, written in bold or large print, etc.), are either property of Sacco, owned by an affiliate or covered by a licensing agreement.

What is presented in this document as a trademark may not be such in your specific country, notwithstanding the potential presence of the ® symbol, due to national registration regulations and processes.

This information is intended for business to business and Healthcare professionals' communication for specific ingredients for food, beverage, and supplement producers.

The statements and information contained herein are not intended for final consumers of finished products. Any claims made for consumers remains the sole responsibility of the marketer of the finished product. This information is provided "as is" and its use is at the recipient's sole discretion and risk. The statements made within this information have not been evaluated by the Food and Drug Administration. These statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.

The introduction of the Product into a market outside the European Union is the sole responsibility of the purchaser. The purchaser must ensure, among other things, that the Product fully complies with the applicable laws and regulations of the relevant territory and fulfills all necessary obligations for lawful market introduction

ActiveServices

MadeForYou

Within the microbiome innovation space, Sacco System emerges as a reliable all-in-one partner. We specialize in handling the intricacies of manufacturing and science, freeing you to concentrate on your core business. Our range of services covers expertise in aerobic and anaerobic strains, Probiotics, Postbiotics, and Microbial Therapeutics, providing versatile solutions tailored to your unique requirements.

Process development & fermentation: from initial development to scale up:



Media screening
and optimization



Analytical method development,
qualification and validation



Molecular biology
& genetic analysis




Cell bank preparation and validation
(RCB, MCB and WCB)



Process development
and scale up



Lyophilization



Possible production in GMP
from clinical to industrial
scale (200L to 20,000L)



Stability studies

Product formulation: Our business development team can support the design of the final concept, from the definition of the scientific rationale to the selection of the most appropriate pharmaceutical form to shortcut your entry into the market.

In vitro and in vivo trials: Defining the experimental design and characterizing your product in vitro or through clinical trials.

Market Expansion: Market analysis, distributor scouting and management, connection to third-party service providers as laboratories, contract manufacturing organizations and authorities.

Regulatory Support: Registration support, new biotherapeutic dossiers.

Molecular biology & laboratory analysis: Several wet labs and in silico assays to better characterize your products.

New Project Ideas

[illegible]

New Project Ideas

[illegible]

Company

Sacco System heritage in Lactic Acid Bacteria (LAB) traces its roots back to 1948, when Dr. Leo Vesely founded Centro Sperimentale del latte, a pioneer company dedicated in studying of bacteria for human health and children's nutrition.

Today we are the international biotech hub for food, nutraceutical, and pharmaceutical industries. Operating in over 110 countries worldwide, Sacco System provides its expertise on probiotic products development and offer science based proprietary strains and customized blends, supporting consumer needs.

Our innovative approach covers production, research and development in nutraceutical and pharmaceutical fields, having available three pilot plants, cutting edge technologies and two facilities GMP Pharmaceutical certified. An expertise extends beyond LAB, following the evolving demands of the market. This includes the development, process validation and commercial production of probiotics, postbiotics, Next-Generation bacteria (obligate aerobes and anaerobes strains) and biotherapeutics (BPs).

Quality


Our quality system is extensive and as a confirmation of our strong commitment to quality, Sacco System has achieved the main certifications over the years.



Contact us to discover the best solution for your business!

 info@saccosystem.com

 **SACCO SYSTEM**

 **SACCO SYSTEM**
Via Alessandro Manzoni, 29/A,
22071 Cadorago CO, Italy